Bioventus09.09.19
Bioventus, a global leader in orthobiologic solutions, has agreed to a nationwide contract with UnitedHealthcare Employer & Individual commercial plans beginning Oct. 1. On that date, UnitedHealthcare commercial plan members will have access to both DUROLANE and GELSYN-3, to treat knee osteoarthritis (OA) pain. DUROLANE, is a single-injection and GELSYN-3, a three-injection hyaluronic acid (HA)-based joint-fluid treatment for patients.
OA involves the breakdown, or degeneration, of cartilage and the synovial fluid that cushions and lubricates joint tissues. Injection treatments of HA-based products, such as DUROLANE and GELSYN-3, help manage knee OA pain.
“We are pleased DUROLANE and GELSYN-3 are among the preferred options available to UnitedHealthcare members and physicians,” said John Nosenzo, chief commercial officer, Bioventus. “Both now have access to two safe HA products that are proven to provide relief from knee OA pain.”
Bioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The orthobiologic products from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide.
DUROLANE is indicated for the treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative non-pharmacological therapy or simple analgesics, e.g. acetaminophen.
GELSYN-3 is indicated for the treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g. acetaminophen).
OA involves the breakdown, or degeneration, of cartilage and the synovial fluid that cushions and lubricates joint tissues. Injection treatments of HA-based products, such as DUROLANE and GELSYN-3, help manage knee OA pain.
“We are pleased DUROLANE and GELSYN-3 are among the preferred options available to UnitedHealthcare members and physicians,” said John Nosenzo, chief commercial officer, Bioventus. “Both now have access to two safe HA products that are proven to provide relief from knee OA pain.”
Bioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The orthobiologic products from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide.
DUROLANE is indicated for the treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative non-pharmacological therapy or simple analgesics, e.g. acetaminophen.
GELSYN-3 is indicated for the treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g. acetaminophen).